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MDM2 (murine double minute-2) links inflammation
and tubular cell healing during acute kidney
injury in mice
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Murine double minute (MDM)-2, an E3 ubiquitin ligase,
promotes cancer cell survival and growth, by degrading
the cell cycle regulator p53. Antagonism of MDM2 by the
small-molecule cis-imidazoline nutlin analogs is under
current study for cancer therapy. To test whether MDM2
also promotes regenerative cell growth, we determined
the effects of nutlin-3a on tubule cell healing during
postischemic acute kidney injury (AKI). Treatment with
nutlin-3a impaired tubular cell regeneration during
postischemic AKI in wild-type mice in a p53-dependent
manner; however, MDM2 blockade also prevented tubular
necrosis by suppressing sterile inflammation during the
early postischemic phase. This effect also occurred in
p53 knockout mice, indicating a second, proinflammatory,
p53-independent role for MDM2 in AKI. In vitro experiments
confirmed that MDM2 is required to induce mRNA expression
and secretion of NFjB-dependent cytokines upon Toll-like
receptor stimulation by enhanced binding of NFjB to
cytokine promoter–binding sites. Thus, MDM2 links
inflammation and epithelial healing during AKI. These
additional biological functions need to be regarded when
considering MDM2 inhibition therapy.
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Acute kidney injury (AKI) is a highly prevalent disorder in
hospitalized patients and an unfavorable prognostic factor
for overall survival. Many different factors can trigger AKI,
including urinary outflow obstructions, nephrotoxic agents,
infections, and renal hypoperfusion or ischemia.1 Ischemia–
reperfusion is a common cofactor in many clinical AKI
settings and unavoidable in renal transplantation where
transient lack of renal perfusion induces oxidative stress
and tubular cell damage. Animal models of postischemic AKI
have provided a detailed understanding of the different
pathomechanisms that are involved in postischemic AKI,
which largely mirror those in dermal wound healing after
acute trauma.1,2 For example, postischemic AKI involves an
early sterile inflammatory response with increased vascular
permeability and Toll-like receptor (TLR)–mediated expres-
sion of proinflammatory cytokines and chemokines in
tubular cells and renal dendritic cells, which is followed by
a rapid influx of neutrophils.1,3,4 Mediators released by this
early neutrophil and the subsequent macrophage infiltrates
largely contribute to acute tubular necrosis and renal
dysfunction, whereas the phagocytic uptake of apoptotic
neutrophils changes the macrophage phenotype in a sense
that the macrophages now release anti-inflammatory cyto-
kines and downregulate renal inflammation.5 It is known
that the early inflammatory response inhibits the process
of epithelial healing in dermal wounds, but, obviously,
the inflammatory response and negative impact on damage
and healing was positively selected throughout evolution,
probably because it prevents fatal sepsis.2,6 However, the
acute inflammatory response was maintained also in sterile
forms of inflammation and contributes to all forms of
ischemia–reperfusion injuries including postischemic AKI.7
The regeneration of dead tubular cells, here referred to as
epithelial healing, starts shortly after the initial inflammatory
response and involves the proliferation of surviving tubular
epithelial cells.8 It is noteworthy that tubular regeneration has
to occur within each damaged nephron, and those nephrons
that fail to rapidly regrow their epithelial monolayer promote
mesenchymal healing, also named interstitial fibrosis.9 The
cellular and molecular mechanisms that regulate tubular cell
death and regeneration in AKI are not completely understood
and remain under debate.10,11
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For example, the cell cycle regulator p53 is involved in
activating multiple proapoptotic genes for tubular cell death
in the early phase of AKI.12,13 The biological activity of p53 is
regulated by murine double minute-2 (MDM2), an E3 ligase
that can inactivate p53 via ubiquitination and proteasomal
degradation or retain inactive p53 in the cytosol.14–16 For
example, MDM2 promotes the survival and proliferation
of malignant cells by p53 inhibition,17,18 or abnormal levels
of MDM2 drive tumorigenesis in malignant cells.19,20 Vice
versa, MDM2 blockade promotes cell cycle arrest or apo-
ptosis via enhanced p53 activation and expression of p53
target genes; hence, specific small-molecule MDM2 inhibi-
tors have been developed21,22 and are currently in clinical
trials for the treatment of various types of cancer.23
We hypothesized that the regulatory role of MDM2 on
p53 is mandatory for limiting p53-dependent tubular cell
apoptosis and for promoting tubular cell regeneration during
AKI. As such we assumed that therapeutic MDM2 inhibition
will aggravate acute tubular necrosis and impair tubular
regeneration in AKI, a theoretical concern that we addressed
by studying the effects of the MDM2 antagonist nutlin-3a in
a model of murine postischemic AKI.
RESULTS
MDM2 expression in the healthy and postischemic kidney
We started out with a MDM2 mRNA expression screen in
solid organs of healthy adult C57BL/6 mice. The highest
MDM2 mRNA expression levels were found in muscle and
heart, whereas the renal MDM2 mRNA levels were more
in the range of lung, colon, urinary bladder, and brain
(Figure 1a). Immunostaining localized MDM2 to the
cytoplasm of epithelial cells in proximal and distal tubuli,
and probably to podocytes inside glomeruli (Figure 1b).
Next, we determined MDM2 expression in postischemic and
sham kidneys 1 and 5 days after renal pedicle clamping by
western blot analysis. MDM2 protein levels were reduced in
both kidneys, postischemic and sham-operated, at day 1 but
MDM2 levels recovered in sham kidneys at day 5 (Figure 1c).
Furthermore, p53 protein expression was strongly induced
in postischemic kidneys at 24 h and remains elevated at day 5
after ischemia–reperfusion. Together, inside the kidney
MDM2 is mainly expressed by (tubular) epithelial cells.
MDM2 blockade prevents early postischemic AKI
To address a putative functional contribution of MDM2 to
AKI, we blocked MDM2 with nutlin-3a, a small-molecule
MDM2 antagonist that inhibits MDM2-mediated degrada-
tion of p53 leading to cell cycle arrest and apoptosis in
various cancer cells.21 We hypothesized that nutlin-3a
treatment would elicit a similar effect in AKI, i.e., foster
p53-mediated tubular cell apoptosis, a process that should
aggravate the early phase of postischemic injury. However,
MDM2 blockade with nutlin-3a rather significantly reduced
serum creatinine levels at 24 h after bilateral renal artery
clamping as compared with vehicle-treated C57BL/6 mice
(Figure 2a). This protective effect was associated with less
tubular injury in postischemic kidneys at 24 h also after
unilateral renal artery clamping (Figures 2b and c), and
immunostaining for either brush border lectin or Tamm–-
Horsfall protein revealed that this protective effect applied
to proximal and distal tubules, respectively (Figure 3). In
AKI, loss of intact tubules involves both tubular cell necrosis
and apoptosis.1 Interestingly, MDM2 blockade significantly
reduced the numbers of terminal deoxytransferase uridine
triphosphate nick end labeling (TUNEL)-positive tubular
cells (Figure 4). These results were unexpected as we rather
anticipated that MDM2 blockade would enhance tubular
cell apoptosis by promoting p53 activation in AKI.24–26 To
verify the potential of nutlin-3a to activate p53 in vivo, we
performed western blots on kidney protein isolates for total
p53 and for phosphorylated, i.e. activated, p53. As expected,
nutlin-3a treatment slightly increased the protein levels of
p53 at 24 h after renal artery clamping (Figure 5), presumably
by inhibiting MDM2-mediated p53 degradation. Further-
more, nutlin-3a treatment slightly increased the protein levels
of activated p53 and also the expression of p53-dependent
apoptotic genes (Figures 5 and 6a), whereas the levels of
MDM2 and phosphorylated MDM2 remained unaffected by
nutlin-3a treatment (Figure 5). Together, MDM2 blockade
with nutlin-3a stabilizes and activates p53 in the postis-
chemic kidney. As p53 activation is known to contribute to
postischemic tubular cell apoptosis and AKI,27 we had to
consider that the protective effect of MDM2 blockade on
early AKI is mediated via another, p53-independent,
pathomechanism of AKI.
MDM2 promotes postischemic renal inflammation in
a p53-independent manner
To verify p53-independent effects of MDM2 blockade in
early AKI, we performed the same set of experiments in
p53-deficient mice (Figure 7 and Supplementary Figure S1
online). A comparison of AKI 24 h after renal artery clamping
revealed no difference in the renal phenotype of wild-type
or p53-deficient mice with nutlin-3a treatment as evidenced
by the tubular injury score or the percentages of lectin or
Tamm–Horsfall protein–positive proximal and distal tubuli,
respectively (Figure 7). Moreover, the numbers of infiltrating
neutrophils, F4/80 macrophages, or CD3 T cells were not
affected by the p53 genotype. In analyzing other disease
pathomechanism of AKI that could involve MDM2 in
a p53-independent manner, we considered postischemic
renal inflammation. Oxidative stress and cell necrosis are
important stimuli of sterile inflammation, and inflammatory
cytokines and infiltrating immune cells contribute to
postischemic tissue injury.28,29 Ischemia–reperfusion strongly
induced intrarenal mRNA expression of several proinflam-
matory mediators such as CXCL2, CCL2, interleukin (IL)-6,
and the proapoptotic cytokine tumor necrosis factor
(TNF)-a within 24 h, an effect that was suppressed by
MDM2 blockade (Figure 8a). Whereas IL-6 expression
derived from different types of resident immune cells and
renal parenchymal cells, MDM2 blockade suppressed the
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induction of TNF-a, CXCL2, and CCL2 mainly in intrarenal
CD11c-positive dendritic cells (Figure 8b). Accordingly, the
numbers of infiltrating neutrophils (but not of F4/80þ
macrophages or CD3þ T cells) were significantly reduced
after 24 h in postischemic kidneys of nutlin-3a-treated wild-
type mice (Figure 9). There were no significant changes in
*
b
a
4.0 × 10–4
5.0 × 10–4
3.0 × 10–4
2.0 × 10–4
M
D
M
2 
m
R
N
A/
18
s 
rR
NA
1.0 × 10–4
0
Lu
ng
Ki
dn
ey
Sm
al
l in
te
st
in
e
Co
lo
n
Bl
ad
de
r
Sk
in
Te
st
is
/u
te
ru
s
Ly
m
ph
 n
od
es
Sp
le
en
Br
a
in
Th
ym
u
s
M
us
cl
e
H
ea
rt
Bo
ne
 m
ar
ro
w
Li
ve
r
c
Baseline
p53
MDM2
β-Actin
IR
Day 1
Sham
Day 1
IR
Day 5
Sham
Day 5
1.5 IR
Co
1.0
0.5
M
D
M
2/
β-a
ct
in
Fo
ld
 in
cr
ea
se
0.0
Baseline Day 1 Day 5
*
*
**
Figure 1 |Renal murine double minute-2 (MDM2) expression. (a) Total mRNA was isolated from different organs of adult C57BL/6 mice
and MDM2 mRNA expression levels were quantified by reverse transcription-polymerase chain reaction. Data are expressed as ratio of
MDM2 mRNA to the respective 18s rRNA level in mean±s.e.m. from samples of five mice. (b) MDM2 immunostaining (red) was performed
on paraffin-embedded kidney samples of adult C57BL/6 mice. Lotus tetragonolobus lectin stains the brush border of proximal tubuli in
green. 4,6-Diamidino-2-phenylindole stains nuclei in blue. Note the cytoplasmic staining pattern of MDM2 in proximal and distal tubuli in
cortex (upper left) and medulla (lower right), which is absent in negative control stains (upper right). Few resident glomerular cells express
MDM2 (lower left). Original magnification  400. (c) The expression of MDM2 and p53 in ischemic–reperfusion (IR) and contralateral (Co)
kidneys at 1 day and 5 days was determined by western blot analysis. b-Actin staining is shown as loading control. The graph on the
right shows a quantitative analysis of several blots. *Po0.05, **Po0.01 vs. baseline.
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MDM2 mRNA expressions in renal cells (Supplementary
Figure S2 online). The given knowledge about MDM2
inhibition by nutlin rather suggests proapoptotic–antiprolif-
erative effects that rule out the assumption of tissue
protection during AKI. Together, MDM2 blockade amelio-
rates postischemic AKI by suppressing the sterile inflamma-
tory response inside the kidney in a p53-independent manner.
MDM2 is required for NF-jB target gene transcription
Next we investigated how MDM2 can affect the expression
of proinflammatory cytokines. We used p53-deficient and
p53/MDM2 double-deficient mouse embryonic fibroblasts
(MEFs) as a reliable and validated experimental system
to identify p53-independent effects of MDM2.30 Because
postischemic renal inflammation is largely mediated via
MyD88 and TLR4,4 we used the TLR4/MyD88 agonist
lipopolysaccharide (LPS) to activate the cells and measured
cytokine production after 18 h by enzyme-linked immuno-
sorbent assay. Lack of MDM2 completely prevented
LPS-induced TNF-a production and strongly reduced IL-6
release by p53-deficient MEFs (Figure 10a). Theoretically, the
difference in cytokine production could be secondary to
different cell survival or cell growth of the two cell lines. This
was ruled out by comparing cell viability and scratch-induced
wound healing of cell monolayers. Both cell lines grew at the
same rate and healed scratch wounds within the same time
interval (Supplementary Figures S3 and S4 online). Thus,
MDM2 is required for TLR-induced cytokine production, an
3.0 5
**
**
a b
c
2.5
2.0
1.5
1.0
0.5
0.0
Vehicle
Control
1 Day 1 Day 5 Days
Ischemia–reperfusion
Nutlin-3a
Ve
hi
cl
e
N
ut
lin
-3
a
IR Co
Day 1 Day 5
IR Co
Vehicle
Nutlin-3a
Se
ru
m
 c
re
at
in
in
e 
(m
g/d
I)
Tu
bu
la
r i
nju
ry 
sc
ore
 (0
–5
)
4
3
2
1
0
Figure 2 |Murine double minute-2 blockade and postischemic acute kidney injury. (a) Serum creatinine levels were determined
24 h after bilateral renal artery clamping. Data are means±s.e.m. from six mice in each group. (b) Tubular injury was quantified on periodic
acid–Schiff (PAS)-stained renal section at day 1 and 5 after unilateral renal artery clamping as described in methods. IR, ischemia–reperfusion
kidney; Co, contralateral kidney. **Po0.01 nutlin-3a- vs. vehicle-treated mice. (c) Representative images from PAS stains of all groups
are shown at original magnification of  100.
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effect that obviously does not require p53. To further explore
the molecular mechanism by which MDM2 promotes
cytokine induction, we investigated the signaling events
occurring after TLR4 activation by western blot analysis,
namely the expression levels of nuclear factor (NF)-kB p65,
IkBa, p38 mitogen-activated protein kinase (MAPK), p44/42
MAPK, and their phosphorylated forms. To verify the results,
we performed a similar set of experiments in J774 macro-
phages treated with MDM2 inhibitor or vehicle. We could
not detect any significant difference between the two
genotypes of MEF, or between nutlin-3-treated and untreated
macrophages, that could explain the lack of LPS-induced
cytokine induction in p53/MDM2 double-deficient MEFs
(Figure 10b, Supplementary Figures S5–S8). Thus, MDM2
should modulate TLR-induced cytokine expression beyond
the level of NF-kB signaling. We next examined whether
MDM2 modulates the capacity of NF-kB to interact with the
promoter region of its target genes, namely the binding
activity of NF-kB to the kB site of the IL-6 promoter. This
was tested by gel-shift analysis of nuclear extracts that were
prepared 1 h after LPS stimulation in both types of cells. Lack
of MDM2 significantly impaired LPS-induced NF-kB bind-
ing activity to the IL-6 promoter (Figure 10c). NF-kB
activation by LPS in the p53-deficient and p53/MDM2-
double deficient MEFs was also examined by using NF-kB-
luciferase reporter assay and showed lower level of activation
a
b
Control
1 Day
Ischemia–reperfusion
1 Day 5 Days
Ve
hi
cle
Nu
tlin
-3
a
Ve
hi
cle
Nu
tlin
-3
a
Day 1 Day 5
Vehicle
Nutlin-3a100
75
50
25
0
**
*
Pe
rc
en
ta
ge
 o
f l
ivi
ng
pr
ox
im
al
 tu
bu
la
r c
el
ls
Vehicle
Nutlin-3a
100
75
50
25
0
Day 1 Day 5
**
**
Pe
rc
en
ta
ge
 o
f l
ivi
ng
di
st
al
  t
ub
ul
ar
 c
el
ls
Figure 3 |Postischemic injury of proximal and distal tubuli. Lotus tetragonolobus lectin staining identified proximal tubuli (a) and
Tamm–Horsfall protein staining identified distal tubuli (b) in postischemic kidneys. The quantitative assessment of tubuli with intact staining
patterns is shown for each staining. Data are means±s.e.m. from six mice in each group. *Po0.05, **Po0.01 nutlin-3a- vs. vehicle-treated
mice. All images are shown at original magnification of  100.
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of NF-kB in the cells lacking MDM2 (Supplementary
Figure S9 online). Together, MDM2 has a p53-independent
function in facilitating the binding of NF-kB to the promoter
of its target genes, an effect that promotes TLR-induced
expression of proinflammatory cytokines or chemokines and
that appears to contribute to postischemic renal inflamma-
tion and AKI.
MDM2 drives tubular regeneration by blocking
p53-mediated cell cycle arrest and apoptosis
Postischemic renal inflammation and tubular damage is
transient and followed by tubular regeneration, which is
similar to epithelial regeneration in other organs including
dermal wound healing.2 Tubular regeneration involves and
requires the proliferation of surviving tubular cells or tubular
progenitors in each single nephron to restore the nephron’s
physiological functions. To address whether MDM2 does also
modulate this phase of AKI, we clamped both renal arteries
for 30min and monitored serum blood urea nitrogen, with
or without nutlin-3a treatment. Nutlin-3a protected renal
function at the early phase but aggrevated it at later phase of
tubular regeneration (Supplementary Figure S10 online).
Furthermore, we studied postischemic and contralateral
kidneys at day 5 after unilateral renal artery clamping for
45min. Although MDM2 blockade had significantly reduced
AKI at day 1 after ischemia–reperfusion, the tubular injury
was rather aggravated at day 5 as compared with vehicle-
treated wild-type mice (Figures 2b, c and 3). MDM2
blockade increased the numbers of TUNEL-positive cells in
postischemic kidneys at day 5 (Figure 4b), indicating that
MDM2 blockade enhanced tubular cell apoptosis in the
regeneration phase of AKI. In fact, MDM2 blockade induced
the intrarenal mRNA expression levels of several proapopto-
tic p53 target genes such as BAX, BAD, BAK, BID, and NOXA
at day 5 after renal artery clamping (Figure 6b). As this effect
was consistent with our initial hypothesis and as MDM2
blockade increased the intrarenal protein levels of p53 and
activated p53 also at day 5 (Figure 5), we questioned whether
this proapoptotic effect of MDM2 blockade is finally p53
dependent. Consistent with this concept, we found p53-
deficient mice to be entirely protected from nutlin-3a-
mediated aggravation of tubular injury and to have less renal
immune cell infiltrates at day 5 as compared with wild-type
mice (Figure 7). Furthermore, lack of MDM2 had no effect
on the healing of scratched monolayers of p53-deficient
MEFs (Supplementary Figure S1 online). In summary,
MDM2 blockade with nutlin-3a suppresses the early post-
ischemic renal inflammation by inhibiting the p53-indepen-
dent effects of MDM2 on NF-kB signaling. In contrast,
nutlin-3a aggravates AKI in the healing phase by inhibiting
the suppressive effect of MDM2 on p53-mediated cell cycle
arrest and apoptosis. We conclude that MDM2 has a dual
role in postischemic AKI as it mediates both renal
inflammation and epithelial regeneration.
DISCUSSION
We had hypothesized that the known suppressive effect of
MDM2 on p53 activity would prevent cell cycle arrest and
cell death upon oxidative stress and, vice versa, that MDM2
blockade would aggravate postischemic AKI. Our finding
that MDM2-mediated suppression of p53 is required for
tubular regeneration in the healing phase of AKI is partially
consistent with this concept. However, as an unexpected
finding, MDM2 also has a p53-independent proinflammatory
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effect in the early injury phase of AKI, a previously unknown
additional function of this molecule. Our findings have
multiple implications. First, MDM2 drives and links post-
ischemic inflammation and epithelial healing, two major
danger response programs upon acute tissue injuries. Second,
MDM2 blockade protected the kidney from AKI despite
enhanced p53 activation documenting that intrarenal inflam-
mation, not oxidative stress per se, accounts for most of the
tubular damage in postischemic AKI. Third, therapeutic
MDM2 blockade, e.g., in cancer, may hold the risk of
impaired (epithelial) healing.
As a new finding, we found MDM2 blockade to inhibit the
induction of proinflammatory mediators that mediate
leukocyte recruitment and tissue damage in the postischemic
kidney. This sterile inflammatory response is triggered by
danger-associated molecules that are released from dying cells
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and that activate TLR2 and TLR4 in renal parenchymal cells
and in intrarenal dendritic cells.3,4,28,29,31–33 The common
signaling adaptor MyD88 links TLR activation to NF-kB
translocation to the nucleus where it binds to the promoter
of multiple proinflammatory target genes such as ILs, TNF,
and chemokines.34 Blocking NF-kB signaling consistently
abrogates postischemic inflammation and AKI,35–37 and
lack of NF-kB signaling inhibitors aggravates renal ischemia–
reperfusion injury.33 Our data now document that MDM2 is
required for TLR-induced NF-kB signaling. MDM2 was
shown to induce the expression of the p65 subunit of NF-kB
by binding to the Sp1 site at the p65 promoter in acute
lymphoblastic leukemia cells,38 but we could not confirm a
MDM2-dependent regulation of p65, IkB, or MAP kinases.
We rather found a nonredundant role of MDM2 for NF-kB
interaction with its binding site at a target gene promoter.
Our observations are consistent with a previous report
showing that MDM2 blockade with nutlin-3a suppresses
LPS-induced lung inflammation and that nutlin-3a impairs
NF-kB DNA binding in neutrophils without affecting other
components of the TLR signaling pathway.39 It is important
to note that this proinflammatory role of MDM2 is p53
independent as clearly documented by our studies with p53-
and p53/MDM2-deficient cells and our studies in wild-type
and p53-deficient mice.
In the postischemic kidney, this p53-independent pro-
inflammatory effect of MDM2 operates simultaneously to its
suppression of p53. This was documented by western blotting
of kidney proteins from nutlin-3a-treated mice, which
displayed a consistent increase of the protein levels of total
p53 and its phosphorylated form. These data document
the dual modulatory effect of MDM2 on p53, i.e., its E3 ligase
activity that degrades p53 and its direct inhibitory effect
on p53 activation.40 Increased p53 activity mediates post-
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T cells (middle graph), and F4/80þ macrophages (lower graph). Neutrophils and T cells were quantified per high-power field (h.p.f.) and
expressed as mean±s.e.m. of 15 h.p.f. Macrophages were quantified by assessing the percentage of staining-positive area via digital
morphometry and are expressed as mean±s.e.m. of 15 h.p.f. *Po0.05, ***Po0.001 vs. wild-type mice.
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ischemic tubular cell death and renal dysfunction, and
blocking p53 activation attenuates AKI.12,13 These data
suggest that MDM2 blockade should aggravate postischemic
AKI. As we found exactly the opposite, we conclude that in
the early phase of AKI the p53-independent proinflammatory
effect of MDM2 overrides its p53-dependent effects. This
finding also clearly documents that postischemic AKI
largely results from secondary inflammatory tissue damage
as an unnecessary and inappropriate danger response to
oxidative stress.
Once the acute inflammatory response had resolved,
MDM2-mediated inhibition of p53’s effects on the induction
of proapoptotic genes and tubular cell death seems to
dominate and to be required for tubular regeneration.
Epithelial healing is an important element of tissue
regeneration after injury of outer or inner surfaces.2 The
regeneration of injured tubular cells is conceptually identical
to (scratch-induced) injury of cell monolayers in culture and
involves the proliferation and migration of surviving
epithelial cells.11 MDM2 blockade impaired this process
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Figure 8 |Murine double minute-2 blockade and inflammatory mediator expression in postischemic kidneys. (a) Total mRNA was
prepared from vehicle- (black bars) or nutlin-3a-treated (white bars) C57BL/6 mice at day 1 or 5 after unilateral renal artery clamping as
indicated. *Po0.05 vs. vehicle-treated mice. (b) CD45þ leukocytes and CD45 renal parenchymal cells were separated from postischemic
kidneys of both treatment groups 24 h after renal artery clamping by magnetic bead isolation as described in Materials and Methods.
The CD45þ cell population was further separated into CD11cþ ‘dendritic cells’ and CD11c other leukocytes. The mRNA expression levels
were determined for the indicated cytokines and chemokines by real-time polymerase chain reaction and are expressed as mean of the
ratio vs. the respective 18s rRNA level±s.e.m. P-levels for the comparison of nutlin-3 vs. vehicle treatment are as indicated. Co, contralateral
‘sham’ kidney; IL, interleukin; IR, clamped kidney; TNF, tumor necrosis factor.
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5 days after renal ischemia–reperfusion by tilting cell cycle
regulation toward p53-dependent tubular cell apoptosis as
evidenced by a lack of this phenomenon in p53-deficient
mice. The capacity of the MDM2 antagonist nutlin-3a to
impair epithelial healing may be clinically important when
nutlins will be used to treat cancer.21,41,42 It should be
considered that the desired antiproliferative and proapoptotic
effects of nutlins in cancer might affect tissue regeneration
upon (renal) injuries or wound healing after surgery.43,44
Together, a rapid inflammatory response and subsequent
epithelial healing represent effective response programs to
minimize the risk of fatal infections after dermal injuries. In
the kidney, however, postischemic inflammation is of no
benefit in this regard but determines largely postischemic
AKI. Our data identify MDM2 as a factor that drives early
postischemic renal inflammation and subsequent epithelial
healing via two independent functional properties, i.e.,
facilitating NF-kB-target gene expression and suppressing
p53-mediated cell cycle arrest and apoptosis, respectively. The
dual role of MDM2 on inflammation and cell cycle control is
conceptually similar to the respective functional roles of the
mammalian target of rapamycin pathway.45 As such, MDM2
blockade, e.g. with nutlins, seems to have similar effects on
cancer cell growth, wound healing, and immunosuppression.
We conclude that MDM2 mediates inflammation and tubular
healing in postischemic AKI.
MATERIALS AND METHODS
Animal studies
C57BL/6 wild-type mice and p53-deficient C57BL/6 mice were
obtained from Taconic (Ry, Denmark) and kept under normal
housing conditions under a 12-h light and dark cycle. Water and
standard chow (Ssniff, Soest, Germany) were available ad libitum.
Mice received intraperitoneal injections with either 20mg/kg of the
MDM2 inhibitor nutlin-3a (Axxora, Lo¨rrach, Germany) in 50%
dimethyl sulfoxide (vehicle) or vehicle only.21 Groups of mice
(n¼ 6) received a single nutlin-3a injection 24 h before renal artery
clamping; others received three injections on the days 1, þ 2, and
þ 3. Renal ischemia–reperfusion was performed under general
anesthesia as previously described.32 In brief, the left or both renal
pedicles were clamped for either 45 or 30min, respectively, with
microaneurysm clamps (Medicon, Tuttlingen, Germany) via 1-cm
flank incisions. Body temperature was continuously measured with
a rectal probe and maintained at 36–37 1C throughout the procedure
by placing the mice on a heating pad. After clamp removal, the
kidney was inspected for restoration of blood flow before closing the
wound with standard sutures. To maintain fluid balance, all mice
were supplemented with 0.5ml of normal saline. Mice were killed
at 24 h or 5 days after surgery, and pieces from ischemic and
contralateral (sham) kidneys were snap-frozen in liquid nitrogen
and fixed in 10% buffered formalin. All experiments were conducted
according to German animal protection laws and had been approved
by the local government authorities.
Histological evaluation
Kidneys were embedded in paraffin and 2 mm sections were used for
periodic acid–Schiff stains and immunostaining as described.32
Postischemic tubular injury was scored by assessing the percentage
of tubules in the corticomedullary junction that displayed cell
necrosis, loss of brush border, cast formation, and tubular dilatation
as follows: 0, none; 1, p10%; 2, 11–25%; 3, 26–45%; 4, 46–75%;
and 5, 476%.46 For histochemistry, we used biotinylated Lotus
tetragonolobus lectin stain (Vector Labs, Burlingame, CA) and
Tamm–Horsfall protein stain (Santa Cruz Biotechnology, Santa
Cruz, CA). For immunostaining, the following primary antibodies
were used: rat anti-mouse neutrophils (Serotec, Oxford, UK), anti-
CD3þ , anti-F4/80 (both Serotec), and rabbit anti-mouse MDM2
(Abcam, Cambridge, UK). A cell death detection (TUNEL) kit
(Roche, Mannheim, Germany) was used to quantify apoptotic cells.
To count interstitial cells, 10 cortical high-power fields ( 400) were
analyzed. All assessments were performed by two blinded observers
(S.R.M. and H.J.A.).
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Figure 9 |Murine double minute-2 blockade and leukocyte
infiltrates in postischemic kidneys. Renal sections from
postischemic (IR) and contralateral kidneys (Co) were stained for
different leukocyte markers as described in methods. Neutrophils
and CD3þ T cells were counted per high-power field (h.p.f.).
F4/80-positive macrophages were quantified by digital
morphometry, and data are expressed as percentage of h.p.f. Data
are means±s.e.m. of 15 h.p.f. from at least six mice in each group.
*Po0.05 vs. vehicle-treated mice of the respective time point.
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Protein isolation and western blotting
Protein from kidney tissues was extracted with lysis buffer (Tris-HCl
50mM, NaCl 150mM, sodium orthovanadate 100mM, sodium
deoxycholate 0.5%, NP40 4%, Triton X-100 2%, EDTA 5mM,
sucrose 300mM, and Roche protease inhibitors) as described.47 Total
cellular extracts were prepared in protein lysis buffer (Tris 10mM,
NaCl 10mM, ethylenediaminetetraacetic acid 10mM, HEPES 1mol/l,
glycerol 20%, MgCl2 1mol/l, dithiothreitol 1mol/l, Triton 10%
sodium fluoride 1mol/l, and Roche protease inhibitors). After
determination of protein concentrations, 50 mg of the kidney protein
or 10 mg of protein extracted from cells was mixed with 5 sodium
dodecyl sulfate loading buffer (100mmol/l Tris-HCl, 4% sodium
dodecyl sulfate, 20% glycerol, and 0.2% bromophenol blue) for
western blot analysis. Samples were heated at 95 1C for 5min.
Proteins were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and then transferred to a polyvinylidene
difluoride membrane. Nonspecific binding to the membrane was
blocked for 2 h at room temperature with 5% bovine serum
albumin in tris-buffered saline buffer (20mmol/l Tris-HCl,
150mmol/l NaCl, and 0.1% Tween 20). The membranes were
then incubated overnight at 4 1C with the following primary
antibodies: anti-mouse p53 and phospho p53 (Santa Cruz
Biotechnology), anti-mouse MDM2 (Abcam), phospho MDM2,
b-actin, anti-P-NF-kB p65, anti-NF-kB p65, anti-IkBa, anti-P-IkBa,
anti-P-p38 MAPK, anti-p38 MAPK, anti-p44/42 MAPK, and anti-
P-p44/42 MAPK (Cell signaling, Danvers, MA). After washing,
the membrane was incubated with peroxidase-conjugated secondary
antibodies in Tris-buffered saline buffer. The signals were visualized
by an enhanced chemiluminescence system (Amersham, Bukin-
ghamshire, UK).
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Figure 10 | In vitro studies with p53- and p53/MDM2-deficient mouse embryonic fibroblasts. (a) Mouse embryonic fibroblasts (MEF)
either deficient for p53 or p53/MDM2 were stimulated with 5 mg/ml LPS, and IL-6 and TNF-a levels in the supernatants were measured
after 18 h. (b) Effect of LPS stimulation of TLR4 on different signaling pathways in both cell lines after 0.5, 1, and 3 h. The graph shows
western blots for the respective TLR signaling proteins. b-Actin is shown as loading control. (c) LPS-induced NF-kB binding to IL-6 promoter
region DNA was studied in both cell lines by electrophoretic mobility shift assay. Binding site–specific competitor DNA and nonspecific
noncompeting DNA were used to document NF-kB’s interaction with the sequence-specific binding site. The data are representative
of three independent experiments. IL, interleukin; LPS, lipopolysaccharide; MDM2, murine double minute-2; ND, not determined;
NF-kB, nuclear factor-kB; TLR, Toll-like receptor.
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RNA preparation and real-time quantitative (TaqMan)
reverse transcription-polymerase chain reaction
Reverse transcription and real-time reverse transcription-poly-
merase chain reaction from total renal RNA or renal cell types
isolated by magnetic bead isolation was prepared as described.33
SYBR Green Dye detection system was used for quantitative real-
time polymerase chain reaction on Light Cycler 480 (Roche,
Mannheim, Germany). Gene-specific primers (300 nM, Metabion,
Martinsried, Germany) were used as listed in Table 1.
Controls consisting of ddH2O were negative for target and
housekeeper genes.
Magnetic cell sorting technique
In brief, kidneys were finely minced and digested for 30min at 37 1C
with 1mg/ml collagenase D (Roche, Mannheim, Germany) and
0.1mg/ml deoxyribonuclease type I (Sigma-Aldrich, Steinheim,
Germany) in Hank’s balanced salt solution. The digested tissues
were washed and filtered through a 30-mm nylon mesh filter to
remove debris and cell segments. Renal CD45þCD11cþ cells were
isolated using microbead-conjugated antibodies (Miltenyi Biotech,
Bergisch-Gladbach, Germany). Magnetic bead separation was done
according to the manufacturer’s instructions.
Cell culture studies
MEFs deficient either for p53 or p53/MDM2 (MEFs) were kindly
provided by Dr G Lozano, University of Houston, TX, and
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and 1% penicillin/streptomycin.30 For
cell stimulation experiments, the cells were seeded at a density of
5 105 cells/well in six-well plates in Dulbecco’s modified Eagle’s
medium and grown overnight to confluence. Cells were treated with
5 mg/ml ultrapure LPS (InvivoGen, San Diego, CA) and incubated at
37 1C, 5% CO2 for 0.5–18 h. Total cell protein was extracted for
western blot analysis and supernatants were collected for IL-6 or
TNF-a enzyme-linked immunosorbent assay (BD OptEIA Mouse
IL-6, BD Biosciences, Mannheim, Germany; Max Standard SET
Mouse TNF-a, Biolegend, San Diego, CA). Nuclear proteins were
isolated by using high-salt extraction.
Electrophoretic mobility shift assay
Electrophoretic mobility shift assay was performed using a LightShift
Chemiluminescent EMSA Kit (Thermo Scientific, Rockford, IL).
Following quantification of protein amounts by Bradford assay, 2mg
of nuclear extracts were analyzed for their binding activity to an IL-6-
derived kB sequence–containing biotin end–labeled oligonucleotide
probe. 50-biotin end-labeled NF-kB oligonucleotides 50-AAATGTGG
GATTTTCCCATGAGTCTC-30 and its reverse counterpart
(Metabion) were annealed for the duplex probe. Binding reaction
and electrophoresis on 6% native polyacrylomide gel were performed
according to the manufacturer’s protocol and transferred on a
nylon membrane. For oligonucleotide competitions, we added
20ng of specific oligonucleotide competitor before adding the probe.
The biotin end-labeled DNA is detected using the Streptavidin-
horseradish peroxidase conjugate and the chemiluminescent
substrate.
Statistical analysis
Data were expressed as mean±s.e.m. Data from vehicle and nutlin-
3a-treated mice were compared with analysis of variance on ranks,
followed by the Student–Newman–Keuls test using the SigmaStat
Software (Jandel Scientific, Erkrath, Germany). T-test was used for
direct comparisons between ischemia–reperfusion and nutlin-3a-
treated ischemia–reperfusion group. A P-value o0.05 indicated
statistical significance.
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SUPPLEMENTARY MATERIAL
Figure S1. Renal Injury phenotype in WT and p53-deficient mice after
45 min unilateral renal artery clamping.
Figure S2. MDM2 mRNA expression levels were determined by real-
time PCR from CD11c+ dendritic cells and CD11c- leukocytes and
non-leukocytes isolated from ischemic and sham kidneys.
Figure S3. Scratch assay.
Figure S4. Proliferation assay.
Figure S5. Effect of LPS stimulation on p53/ and MDM2/p53/
MEFs.
Figure S6. Densitometric quantification of p53/ and MDM2/p53/
MEFs western blots from supplementary Figure S5.
Figure S7. Effect of LPS stimulation on J774 macrophages treated
with nutlin-3 or vehicle.
Figure S8. Densitometric quantification of J774 western blots from
supplementary Figure S7.
Figure S9. NFkB luciferase reporter assay
Figure S10. MDM2 blockade and postischemic AKI.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki.
Table 1 | Primers used for real-time reverse transcription-
polymerase chain reaction
Target Primer sequence
MDM2 Forward primer 50-TGTGAAGGAGCACAGGAAAA-30
Reverse primer 50-TCCTTCAGATCACTCCCACC-30
CXCL2 Forward primer 50-CGGTCAAAAAGTTTGCCTTG-30
Reverse primer 50-TCCAGGTCAGTTAGCCTTGC-30
CCL2 Forward primer 50-CCTGCTGTTCACAGTTGCC-30
Reverse primer 50-ATTGGGATCATCTTGCTGGT-30
IL-6 Forward primer 50-TGATGCACTTGCAGAAAACA-30
Reverse primer 50-ACCAGAGGAAATTTTCAATAGGC-30
TNF-a Forward primer 50-CCACCACGCTCTTCTGTCTAC-30
Reverse primer 50-AGGGTCTGGGCCATAGAACT-30
BAX Forward primer 50-GATCAGCTCGGGCACTTTAG-30
Reverse primer 50-TTGCTGATGGCAACTTCAAC-30
BAD Forward primer 50-GTACGAACTGTGGCGACTCC-30
Reverse primer 50-GAGCAACATTCATCAGCAGG-30
BAK1 Forward primer 50-AGACCTCCTCTGTGTCCTGG-30
Reverse primer 50-AAAATGGCATCTGGACAAGG-30
BID Forward primer 50-GTGTAGCTCCAAGCACTGCC-30
Reverse primer 50-GCAAACCTTTGCCTTAGCC-30
NOXA Forward primer 50-ACTTTGTCTCCAATCCTCCG-30
Reverse primer 50-GAAGTCGCAAAAGAGCAGGA-30
PUMA Forward primer 50-CACCTAGTTGGGCTCCATTT-30
Reverse primer 50-ACCTCAACGCGCAGTACG-30
18 s RNA Forward primer 50-GCAATTATTCCCCATGAACG-30
Reverse primer 50-AGGGCCTCACTAAACCATCC-30
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